摘要
Background Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor ( EGFR )–positive non-small cell lung cancer (NSCLC). However, it remains unclear whether upfront osimertinib is superior to sequential first- or second-generation tyrosine kinase inhibitors (TKIs) followed by osimertinib for all patients. It is impossible to predict which patients are at high risk of progression, and this constitutes a major limitation of the sequential TKI approach.;Patients and methods A total of 830 plasma samples from 228 patients with stage IV, EGFR -positive NSCLC who were treated with first-line TKIs were analysed by digital polymerase chain reaction (dPCR).;Results The circulating tumour DNA (ctDNA) levels helped to identify patients with significantly improved survival rate, regardless of the treatment. Patients treated with first- or second-generation TKIs (N = 189) with EGFR mutations in plasma at a mutant allele frequency (MAF) <7% before treatment initiation (low-risk patients) or who were ctDNA negative after 3 or 6 months of treatment and with an MAF <7% at diagnosis (high responders) had two-thirds lower risk of death than patients in the opposite situation (adjusted hazard ratio [HR] = 0.38; 95% confidence interval [CI]: 0.23–0.64 and HR = 0.22; 95% CI: 0.12–0.42, respectively). The median overall survival (OS) for low-risk patients and high responders treated with first- or second-generation TKIs was 34.2 months and not reached, respectively, regardless of second-line treatment. There were no significant difference in OS between low-risk or high-responder patients treated upfront with osimertinib (N = 39) and those treated under a sequential approach with osimertinib (N = 60). Median OS was not reached in both cases.;Conclusions Pre-treatment ctDNA levels identify low-risk patients, who may benefit from sequential TKI treatment. Information regarding EGFR mutation clearance can help to improve patient selection.
学科与关键词
- Circulating tumor DNA analysis of EGFR -mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatmentJamie J. Beagan; Sander Bach; Robert A. van Boerdonk; Erik van Dijk; Erik Thunnissen; Daan van den Broek; Janneke Weiss; Geert Kazemier; D Michiel Pegtel; Idris Bahce; Bauke Ylstra; Daniëlle A.M. HeidemanLung Cancer, 2020, 145: 173-180.被引 6
- Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patientsEva Boysen Fynboe Ebert; Tine McCulloch; Karin Holmskov Hansen; Hanne Linnet; Boe Sorensen; Peter Meldgaard2020.
- Serial plasma cell-free circulating tumor DNA tests identify genomic alterations for early prediction of osimertinib treatment outcome in EGFR T790M-positive non-small cell lung cancerBin-Chi Liao; Wei-Hsun Hsu; Jih-Hsiang Lee; Ching-Yao Yang; Tzu-Hsiu Tsai; Wei-Yu Liao; Chao-Chi Ho; Chia-Chi Lin; Jin-Yuan Shih; Chong-Jen Yu; Ross A. Soo; James Chih-Hsin YangJTO Clinical and Research Reports, 2020, 100099.
